Safety and Feasibility of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy With Calcium-Containing Solutions : A Randomized Controlled Trial
© 2024 The Authors. Seminars in Dialysis published by Wiley Periodicals LLC..
BACKGROUND: Calcium-free (Ca-free) solutions are theoretically the most ideal for regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT). However, the majority of medical centers in China had to make a compromise of using commercially available calcium-containing (Ca-containing) solutions instead of Ca-free ones due to their scarcity. This study was designed to probe into the potential of Ca-containing solution as a secure and efficient substitution for Ca-free solutions.
METHODS: In this prospective, randomized single-center trial, 99 patients scheduled for CRRT were randomly assigned in a 1:1:1 ratio to one of three treatment groups: continuous veno-venous hemodialysis Ca-free dialysate (CVVHD Ca-free) group, continuous veno-venous hemodiafiltration calcium-free dialysate (CVVHDF Ca-free) group, and continuous veno-venous hemodiafiltration Ca-containing dialysate (CVVHDF Ca-containing) group at cardiac intensive care unit (CICU). The primary endpoint was the incidence of metabolic complications. The secondary endpoints included premature termination of treatment, thrombus of filter, and bubble trap after the process.
RESULTS: The incidence of citrate accumulation (18.2% vs. 12.1% vs. 21.2%) and metabolic alkalosis (12.1% vs. 0% vs. 9.1%) did not significantly differ among three groups (p > 0.05 for both). The incidence of premature termination was comparable among the groups (18.2% vs. 9.1% vs. 9.1%, p = 0.582). The thrombus level of the filter and bubble trap was similar in the three groups (p > 0.05 for all).
CONCLUSIONS: In RCA-CRRT for CICU population, RCA-CVVHDF with Ca-containing solutions and traditional RCA with Ca-free solutions had a comparable safety and feasibility.
TRIAL REGISTRATION: ChiCTR2100048238 in the Chinese Clinical Trial Registry.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Seminars in dialysis - 37(2024), 3 vom: 12. Apr., Seite 249-258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Shan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/sdi.13200 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369295498 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369295498 | ||
| 003 | DE-627 | ||
| 005 | 20240425233036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/sdi.13200 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369295498 | ||
| 035 | |a (NLM)38439685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Shan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Feasibility of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy With Calcium-Containing Solutions |b A Randomized Controlled Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Seminars in Dialysis published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Calcium-free (Ca-free) solutions are theoretically the most ideal for regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT). However, the majority of medical centers in China had to make a compromise of using commercially available calcium-containing (Ca-containing) solutions instead of Ca-free ones due to their scarcity. This study was designed to probe into the potential of Ca-containing solution as a secure and efficient substitution for Ca-free solutions | ||
| 520 | |a METHODS: In this prospective, randomized single-center trial, 99 patients scheduled for CRRT were randomly assigned in a 1:1:1 ratio to one of three treatment groups: continuous veno-venous hemodialysis Ca-free dialysate (CVVHD Ca-free) group, continuous veno-venous hemodiafiltration calcium-free dialysate (CVVHDF Ca-free) group, and continuous veno-venous hemodiafiltration Ca-containing dialysate (CVVHDF Ca-containing) group at cardiac intensive care unit (CICU). The primary endpoint was the incidence of metabolic complications. The secondary endpoints included premature termination of treatment, thrombus of filter, and bubble trap after the process | ||
| 520 | |a RESULTS: The incidence of citrate accumulation (18.2% vs. 12.1% vs. 21.2%) and metabolic alkalosis (12.1% vs. 0% vs. 9.1%) did not significantly differ among three groups (p > 0.05 for both). The incidence of premature termination was comparable among the groups (18.2% vs. 9.1% vs. 9.1%, p = 0.582). The thrombus level of the filter and bubble trap was similar in the three groups (p > 0.05 for all) | ||
| 520 | |a CONCLUSIONS: In RCA-CRRT for CICU population, RCA-CVVHDF with Ca-containing solutions and traditional RCA with Ca-free solutions had a comparable safety and feasibility | ||
| 520 | |a TRIAL REGISTRATION: ChiCTR2100048238 in the Chinese Clinical Trial Registry | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a calcium‐containing solutions | |
| 650 | 4 | |a continuous renal replacement therapy | |
| 650 | 4 | |a metabolic complications | |
| 650 | 4 | |a regional citrate anticoagulation | |
| 650 | 4 | |a thrombus | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Citric Acid |2 NLM | |
| 650 | 7 | |a 2968PHW8QP |2 NLM | |
| 650 | 7 | |a Dialysis Solutions |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 700 | 1 | |a Sun, Guangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Penglong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, LinJing |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hongfei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xixing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Liyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Lingling |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Fanqi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in dialysis |d 1990 |g 37(2024), 3 vom: 12. Apr., Seite 249-258 |w (DE-627)NLM088787761 |x 1525-139X |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2024 |g number:3 |g day:12 |g month:04 |g pages:249-258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/sdi.13200 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2024 |e 3 |b 12 |c 04 |h 249-258 | ||